Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma

Liu, Weifeng; Hu, Jie; Zhou, Kaiyu; Chen, Feiyu; Wang, Zheng; Liao, Boyi; Dai, Zhi; Cao, Yang; Fan, Jia; Zhou, Jian

doi:10.2147/ott.s140062

Cited by 130 publications

(98 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is consistent with that of previous studies focusing on other cancers [7][8][9][10][11]. Another study also found that a high expression of miR-125b and some other adverse factors (i.e., FLT3 mutation and MLL mutation) had a synergistic effect, and showed a 4-to 8-fold increased risk of relapse and overall death in patients.…”

Section: Discussionsupporting

confidence: 91%

“…MiR-125b may predict prognosis in several types of digestive, respiratory, and nervous system cancers partly through regulating cell migration, invasion, and therapeutic response [7][8][9][10][11][12][13][14]. The potential role of miR-125b in hematological malignances has also been explored in cell, animal, and tissue levels [15][16][17].…”

Section: Discussionmentioning

confidence: 99%

“…A number of studies suggested that miR-125b was a novel prognostic marker for patients with liver cancer, gastric cancer, colorectal cancer, lung cancer, or glioma [7][8][9][10][11]. Additionally, some studies further reported that miR-125b was related to cell migration, invasion, and therapeutic resistance in gastric cancer and breast cancer [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia

et al. 2018

View full text Add to dashboard Cite

Background: The prognostic significance of miR-125b in intermediate-risk acute myeloid leukemia has not been well investigated. The aim of the study was to reveal the relationship between the elevated exosomal miR-125b level and the poor prognosis in adult patients with this disease. Methods: A total of 154 consecutive patients with intermediate-risk acute myeloid leukemia were enrolled. Exosomes were isolated from blood specimens. The exosomal miR-125b level was determined using quantitative real-time polymerase chain reaction. Patients received standardized therapy and were followed up for 1–24 months. Details about relapse and overall death were recorded. Results: Patients were divided into the high miR-125b level group (n = 77) and the low miR-125b level group (n = 77). In the multivariate Cox proportional hazard regression model, the high miR-125b level group was separately associated with increased risks of relapse and overall death in 2 years (hazard ratio [HR] 2.84, 95% CI 1.81–4.33 and HR 2.69, 95% CI 1.87–4.52). Kaplan-Meier analysis also revealed that a high miR-125b level was related to a higher cumulative relapse and overall death rates (p < 0.001 and p < 0.001, respectively). Conclusion: Circulating exosomal miR-125b concentration might be an independent prognostic indicator in intermediate-risk acute myeloid leukemia patients. An elevated miR-125b level indicated higher risks of relapse and overall death.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, the mechanism by which miR-125b regulates MM remains unknown. Importantly, circulating miR-125b-5p has been reported to be correlated with colorectal cancer (30), breast cancer (31) and hepatocellular carcinoma (32). Circulating and serum-derived miRNAs have also been identified in MM patients (33).…”

Section: Discussionmentioning

confidence: 99%

The diagnostic and prognostic value of plasma microRNA‑125b‑5p in patients with multiple myeloma

et al. 2018

View full text Add to dashboard Cite

Abstract. Aberrant expression of microRNAs (miRNAs) contributes to the progression and outcomes of several types of tumor, while circulating miRNAs have been reported to act as biomarkers for several types of cancer. To identify specific circulating miRNAs associated with multiple myeloma (MM), a miRNA microarray analysis was used, which identified 8 upregulated miRNAs and 4 downregulated miRNAs in the plasma of 6 patients with MM compared with 6 healthy individuals. Based on the microarray results, the 8 miRNAs (miR-125b-5p, miR-483-3p, miR-4326, miR-6894-3p, miR-4498, miR-490-3p, miR-7155-5p and miR-937-3p), which were notably upregulated in MM patients were chosen for a second clinical study in 20 healthy controls and 35 patients with MM using reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic analysis demonstrated that miR-125b-5p and miR-490-3p displayed considerable diagnostic accuracy for MM with areas under the curve of 0.954 (P<0.001) and 0.866 (P=0.028), respectively. In addition, the plasma level of miR-125b-5p was associated with the international staging system disease stage. Patients with higher levels of plasma miR-125b-5p had a significantly shorter event-free survival. However, miR-490-3p levels were not associated with event-free survival (P>0.05). In summary, miR-125b-5p may serve as a potential clinical biomarker for MM.

show abstract

“…High expression of HOXB8 plays an important role in the progression and recurrence of HCC [20] . Exosomes extracted from serum samples collected from two cohorts of HCC patients showed high levels of miR-125b which was an independent predictive factor for postoperative recurrence and overall survival of HCC patients [39] . Serum exosomal miR-665 levels were significantly higher in HCC patients than those in healthy subjects.…”

Section: Exosomal Rna Biomarkersmentioning

confidence: 92%

Exosome-based liquid biopsy in the management of hepatocellular carcinoma

Jayachandran¹,

Manda²,

Shrestha³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) commonly presents at an advanced stage due to the lack of efficient early screening tools. Early, non-invasive biomarkers useful in the diagnosis and prognosis of HCC would be of significant benefit for HCC management. Development of exosome-based liquid biopsy as a non-invasive method for the management of HCC has gained much traction. Exosomes are small membranous vesicles secreted by most cell types including HCC cells. Exosomes serve as couriers for the intercellular transfer of important biomolecules, including, protein, nucleic acids and lipids to nearby and distant cells in the body. The molecular cargos carried by exosome have been described to play significant roles in cancer progression. Herein, we will dissect how HCC-derived exosomes confer aggressive traits such as tumour growth, invasion, immune remodelling and drug resistance to HCC cells. We review the current literature concerning exosomes as biomarkers in a diagnostic setting, evaluating their prognostic, predictive and monitoring capabilities. This review will highlight and discuss emerging research in the utility of exosome-based liquid biopsies therapeutic tools in HCC management. Here we will also focus on advances in exosome biology in preclinical studies.

show abstract

Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma

Cited by 130 publications

References 32 publications

Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia

Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia

The diagnostic and prognostic value of plasma microRNA‑125b‑5p in patients with multiple myeloma

Exosome-based liquid biopsy in the management of hepatocellular carcinoma

Contact Info

Product

Resources

About